Sun Pharma Advanced Research Company Limited (SPARC.NS)
INR 145.48
(1.29%)
INR 145.48
(1.29%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 391.06 Million INR | -280.63% |
| 2022 | 592 Million INR | 461.04% |
| 2021 | 105.51 Million INR | -77.33% |
| 2020 | 465.55 Million INR | 139.99% |
| 2019 | -1.16 Billion INR | -618.72% |
| 2018 | 224.41 Million INR | 134.05% |
| 2017 | -659.1 Million INR | -760.04% |
| 2016 | 99.85 Million INR | -56.34% |
| 2015 | 228.69 Million INR | -34.71% |
| 2014 | 350.28 Million INR | -77.97% |
| 2013 | 1.59 Billion INR | 103.94% |
| 2012 | 779.73 Million INR | 261.64% |
| 2011 | 215.61 Million INR | -57.44% |
| 2010 | 506.65 Million INR | 83.28% |
| 2009 | 276.44 Million INR | 7.3% |
| 2008 | 257.64 Million INR | -15.81% |
| 2007 | 306.01 Million INR | 0.0% |
| 2006 | - INR | 0.0% |
| 2005 | - INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -451.2 Million INR | -2.55% |
| 2024 Q2 | -370.9 Million INR | 17.8% |
| 2023 Q4 | -440 Million INR | -133.05% |
| 2023 Q3 | -188.8 Million INR | -439.43% |
| 2023 Q2 | -35 Million INR | 80.77% |
| 2023 Q1 | -182 Million INR | 25.35% |
| 2023 FY | -1.06 Billion INR | -280.63% |
| 2022 Q3 | 952.3 Million INR | 7206.72% |
| 2022 Q1 | -103.1 Million INR | 29.52% |
| 2022 FY | 592 Million INR | 461.04% |
| 2022 Q4 | -243.8 Million INR | -125.6% |
| 2022 Q2 | -13.4 Million INR | 87.0% |
| 2021 Q2 | -31 Million INR | 44.44% |
| 2021 Q4 | -146.28 Million INR | -140.32% |
| 2021 Q1 | -55.8 Million INR | 23.29% |
| 2021 Q3 | 362.8 Million INR | 1270.32% |
| 2021 FY | 105.51 Million INR | -77.33% |
| 2020 Q2 | -433.3 Million INR | -137.25% |
| 2020 Q3 | -191.6 Million INR | 55.78% |
| 2020 FY | 465.55 Million INR | 139.99% |
| 2020 Q4 | -72.74 Million INR | 62.03% |
| 2020 Q1 | 1.16 Billion INR | 338.71% |
| 2019 Q4 | -487.29 Million INR | -320.08% |
| 2019 Q3 | -116 Million INR | 39.24% |
| 2019 FY | -1.16 Billion INR | -618.72% |
| 2019 Q1 | -369.9 Million INR | -234.11% |
| 2019 Q2 | -190.9 Million INR | 48.39% |
| 2018 FY | 224.41 Million INR | 134.05% |
| 2018 Q1 | -167.3 Million INR | -567.32% |
| 2018 Q3 | -251 Million INR | -168.41% |
| 2018 Q4 | 275.81 Million INR | 209.89% |
| 2018 Q2 | 366.9 Million INR | 319.31% |
| 2017 Q4 | 35.8 Million INR | 114.99% |
| 2017 FY | -659.1 Million INR | -760.04% |
| 2017 Q3 | -238.8 Million INR | 5.69% |
| 2017 Q2 | -253.2 Million INR | 36.03% |
| 2017 Q1 | -395.8 Million INR | -2455.95% |
| 2016 Q1 | -58.8 Million INR | -142.0% |
| 2016 FY | 99.85 Million INR | -56.34% |
| 2016 Q4 | 16.8 Million INR | 105.28% |
| 2016 Q3 | -318.4 Million INR | -169.19% |
| 2016 Q2 | 460.2 Million INR | 882.65% |
| 2015 Q3 | -194.7 Million INR | -306.91% |
| 2015 Q4 | 140 Million INR | 171.91% |
| 2015 FY | 228.69 Million INR | -34.71% |
| 2015 Q1 | 189.3 Million INR | 59.24% |
| 2015 Q2 | 94.1 Million INR | -50.29% |
| 2014 Q3 | -7.7 Million INR | -104.43% |
| 2014 Q1 | 67.8 Million INR | -91.06% |
| 2014 Q4 | 118.88 Million INR | 1643.9% |
| 2014 FY | 350.28 Million INR | -77.97% |
| 2014 Q2 | 173.7 Million INR | 156.19% |
| 2013 Q3 | 500.9 Million INR | 547.99% |
| 2013 Q1 | 253.4 Million INR | -74.97% |
| 2013 FY | 1.59 Billion INR | 103.94% |
| 2013 Q4 | 758.61 Million INR | 51.45% |
| 2013 Q2 | 77.3 Million INR | -69.49% |
| 2012 Q2 | -101.5 Million INR | -150.62% |
| 2012 Q1 | -40.5 Million INR | -110.93% |
| 2012 FY | 779.73 Million INR | 261.64% |
| 2012 Q4 | 1.01 Billion INR | 1213.9% |
| 2012 Q3 | -90.9 Million INR | 10.44% |
| 2011 FY | 215.61 Million INR | -57.44% |
| 2011 Q4 | 370.41 Million INR | 703.27% |
| 2011 Q3 | -61.4 Million INR | 0.0% |
| 2010 FY | 506.65 Million INR | 83.28% |
| 2009 FY | 276.44 Million INR | 7.3% |
| 2008 FY | 257.64 Million INR | -15.81% |
| 2007 FY | 306.01 Million INR | 0.0% |
| 2006 FY | - INR | 0.0% |
| 2005 FY | - INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 98.54% |
| Hester Biosciences Limited | 1.27 Billion INR | 69.296% |
| Aarti Drugs Limited | 8.31 Billion INR | 95.298% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 93.294% |
| Albert David Limited | 1.4 Billion INR | 72.227% |
| Alembic Limited | 1 Billion INR | 60.898% |
| Alkem Laboratories Limited | 52.29 Billion INR | 99.252% |
| Bafna Pharmaceuticals Limited | 452.15 Million INR | 13.51% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 73.43% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.54 Million INR | -3017.306% |
| Brooks Laboratories Limited | 65.62 Million INR | -495.956% |
| Eris Lifesciences Limited | 10.42 Billion INR | 96.249% |
| FDC Limited | 6.58 Billion INR | 94.062% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 96.855% |
| Gufic Biosciences Limited | 4.07 Billion INR | 90.4% |
| Hikal Limited | 5.95 Billion INR | 93.436% |
| Ind-Swift Limited | 2.17 Billion INR | 82.0% |
| Innova Captab Limited | 3.46 Billion INR | 88.712% |
| IOL Chemicals and Pharmaceuticals Limited | 4.71 Billion INR | 91.713% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | 40.075% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 98.009% |
| Lincoln Pharmaceuticals Limited | 1.88 Billion INR | 79.274% |
| Lupin Limited | 125.09 Billion INR | 99.687% |
| Mangalam Drugs & Organics Limited | 691.19 Million INR | 43.422% |
| Medico Remedies Limited | 262.14 Million INR | -49.18% |
| Morepen Laboratories Limited | 6.16 Billion INR | 93.653% |
| Nectar Lifesciences Limited | 4.82 Billion INR | 91.892% |
| Orchid Pharma Limited | 2.32 Billion INR | 83.146% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 93.236% |
| RPG Life Sciences Limited | 2.48 Billion INR | 84.25% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | 36.973% |
| Sigachi Industries Limited | 2 Billion INR | 80.469% |
| Solara Active Pharma Sciences Limited | -1.65 Billion INR | 123.617% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 90.516% |
| Themis Medicare Limited | 2.42 Billion INR | 83.84% |
| Unichem Laboratories Limited | 4.86 Billion INR | 91.962% |
| Vaishali Pharma Limited | 90.32 Million INR | -332.964% |
| Wanbury Limited | 1.73 Billion INR | 77.403% |
| Windlas Biotech Limited | 1.33 Billion INR | 70.79% |
| ZIM Laboratories Limited | 1.26 Billion INR | 69.154% |
| Ind-Swift Laboratories Limited | 4.13 Billion INR | 90.538% |
| Ipca Laboratories Limited | 48.58 Billion INR | 99.195% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.849% |
| Venus Remedies Limited | 2.18 Billion INR | 82.082% |
| Sakar Healthcare Limited | 699.58 Million INR | 44.1% |
| Aurobindo Pharma Limited | 109.54 Billion INR | 99.643% |
| Divi's Laboratories Limited | 32.44 Billion INR | 98.794% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 93.715% |
| Mankind Pharma Limited | 42.19 Billion INR | 99.073% |
| Sequent Scientific Limited | 2.97 Billion INR | 86.871% |
| Laurus Labs Limited | 15.44 Billion INR | 97.469% |
| Neuland Laboratories Limited | 8.24 Billion INR | 95.259% |
| J. B. Chemicals & Pharmaceuticals Limited | 15.25 Billion INR | 97.437% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 99.436% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.688% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | 81.325% |
| Wockhardt Limited | 7.72 Billion INR | 94.934% |
| Bal Pharma Limited | 770.19 Million INR | 49.225% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.761% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 89.418% |
| Par Drugs and Chemicals Limited | 529.13 Million INR | 26.093% |
| Caplin Point Laboratories Limited | 9.2 Billion INR | 95.752% |
| Shilpa Medicare Limited | 3.56 Billion INR | 89.021% |
| Valiant Laboratories Limited | 138.02 Million INR | -183.322% |
| Ajanta Pharma Limited | 21.06 Billion INR | 98.143% |
| Aarey Drugs & Pharmaceuticals Limited | 113.02 Million INR | -245.987% |
| Granules India Limited | 16.79 Billion INR | 97.672% |
| Medicamen Biotech Limited | 495.49 Million INR | 21.076% |
| Syncom Formulations (India) Limited | 559.5 Million INR | 30.105% |
| Piramal Enterprises Limited | 8.04 Billion INR | 95.138% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 99.164% |
| NATCO Pharma Limited | 25.73 Billion INR | 98.48% |
| Suven Life Sciences Limited | -200.79 Million INR | 294.757% |
| Krebs Biochemicals & Industries Limited | -108.74 Million INR | 459.611% |
| Strides Pharma Science Limited | 14.38 Billion INR | 97.282% |
| Indoco Remedies Limited | 8.04 Billion INR | 95.138% |
| Alpa Laboratories Limited | 188.89 Million INR | -107.028% |
| Lasa Supergenerics Limited | 121.02 Million INR | -223.115% |